Evidence map›Paper›PMID 40104696›Full record

ArticleTranslational cancer research2025

A novel machine learning-driven immunogenic cell death signature for predicting ovarian cancer prognosis.

Yali Wang, Peng Zhao, Xude Sun, Felipe Batalini, Gabriel Levin, Hooman Soleymani Majd, Hao Chen, Tingting Gao

Abstract read
In one paragraph

Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yali WangDepartment of Obstetrics and Gynecology, Maternal and Child Health Center in Fuping County, Fuping, China.
Peng ZhaoOncology Department, Xi'an Daxing Hospital, Xi'an, China.
Xude SunDepartment of Anesthesia, The Second Affiliated Hospital of Air Force Medical University, Xi'an, China.
Felipe BataliniDepartment of Medical Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA.
Gabriel LevinDivision of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, QC, Canada.
Hooman Soleymani MajdOxford University Hospitals NHS Foundation Trust, Department of Gynaecology Oncology, Churchill Hospital, Oxford, United Kingdom.ORCID https://orcid.org/0000-0002-7603-9986
Hao ChenDepartment of Thoracic Surgery, Tangdu Hospital of Air Force Military Medical University, Xi'an, China.
Tingting GaoDepartment of Obstetrics and Gynecology, The Second Affiliated Hospital of Air Force Medical University, Xi'an, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ovarian cancer (OC) is one of the most lethal malignancies in women, primarily due to the absence of reliable predictive biomarkers and effective therapies. The complex role of immunogenic cell death (ICD) in OC remains poorly understood, despite its critical implications for enhancing immune responses against tumors. We are committed to developing and validating a novel ICD-related gene signature and producing certain guiding value for the clinical treatment of OC. Methods: We employed single-sample gene set enrichment analysis (ssGSEA) and weighted gene coexpression network analysis (WGCNA) on The Cancer Genome Atlas (TCGA)-ovarian carcinoma dataset to identify ICD-associated genes. A combination of 10 different machine learning approaches was used to construct an ICD-related signature (ICDRS), which was then validated across multiple datasets. The model's predictive power was integrated into a clinical nomogram to predict patient outcomes. Ultimately, we assessed the reaction of various risk subgroups to screen pharmaceuticals designed to address specific risk factors in the context of personalized medicine. Results: We identified 72 prognostic genes related to ICD. An unanimous ICDRS was developed using a 101-combination machine learning computational structure, demonstrating outstanding predictive accuracy for prognosis and clinical use. Patients categorized as low ICDRS varied from those of high ICDRS in terms of biological processes, mutation profiles, and immune cell penetration in the tumor microenvironment. In addition, potential medications that target specific subgroups at risk were identified. Conclusions: The ICDRS presents a significant advancement for prognostication of patients with OC, facilitating refined predictions and the exploration of personalized treatment pathways. Prospective clinical trials are necessary to validate its clinical utility and expand the application of this model to other cancer types.

Indexed as

Machine learningovarian cancer (OC)tumor microenvironment

Identifiers

PMID40104696
PMCPMC11912067

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.